Endocrinol Metab > Volume 31(2); 2016 > Article
Jung: Prediction of Diabetes Using Serum C-Peptide
Type 2 diabetes is generally regarded as an irreversible disease, and considering its effects on complications, prevention of diabetes is very important. Fortunately, type 2 diabetes is a preventable disease [1], and therefore the prediction of diabetes in high risk persons is a key issue. Such a prediction would be based on several genetic and environmental factors as well as insulin secretory capacity [2,3], because if the insulin secretion is enough to compensate for other risk factors, diabetes would not develop [4].
In this issue of Endocrinology and Metabolism, Kim et al. [5] suggested that C-peptide would be more effective in the prediction of diabetes compared to insulin. Among 140 adults without diabetes at baseline, 20% became diabetic during a mean follow-up of 55 months, and among the baseline examinations, C-peptide increase by glucose loading—which the authors referred to as the "C-peptidogenic index"—was the most predictive and independent index for future diabetes. Most previous studies have used serum insulin for the estimation of insulin secretion in the prediction of diabetes [2,3,4]; however, according to this study by Kim et al. [5], C-peptide measurement would be superior, especially during oral glucose tolerance tests. In addition, there is a report that the C-peptide based index was more closely correlated than the insulin-based index with β-cell mass in humans [6].
These findings that C-peptide is more related with β-cell mass and function than insulin might be a result of C-peptide metabolism being less vulnerable than insulin and more reproducible with lower variations [7,8].
Although this study was performed as a retrospective design, it is worth paying attention to the results because of the increased prevalence of prediabetes worldwide. Further investigation in large cohort as a prospective design would be needed to establish more accurate tools for the prediction of diabetes.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
[CROSSREF]  [PUBMED]  [PMC] 
2. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care 2013;36:3607-3612.
[CROSSREF]  [PUBMED]  [PMC] 
3. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care 2007;30:1544-1548.
[CROSSREF]  [PUBMED] 
4. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005;54:166-174.
[CROSSREF]  [PUBMED] 
5. Kim JD, Kang SJ, Lee MK, Park SE, Rhee EJ, Park CY, et al. C-peptide-based index is more related to incident type 2 diabetes in non-diabetic subjects than insulin-based index. Endocrinol Metab 2016;31:320-327.
[CROSSREF] 
6. Meier JJ, Menge BA, Breuer TG, Muller CA, Tannapfel A, Uhl W, et al. Functional assessment of pancreatic beta-cell area in humans. Diabetes 2009;58:1595-1603.
[CROSSREF]  [PUBMED]  [PMC] 
7. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377.
[CROSSREF] 
8. Utzschneider KM, Prigeon RL, Tong J, Gerchman F, Carr DB, Zraika S, et al. Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. Diabetologia 2007;50:2516-2525.
[CROSSREF]  [PUBMED]  [PDF]
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 743 View
  • 4 Download
ORCID iDs

Hye Seung Jung
https://orcid.org/0000-0002-0221-7049

Related articles


Editorial Office
101-2503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-716-2428    Fax: +82-2-714-5103    E-mail: journal@endocrinology.or.kr                

Copyright © 2021 by Korean Endocrine Society. All rights reserved.

Developed in M2PI

Close layer
prev next